hypertension, type 2 DM, dyslipidemia) A meta-analysis of 22 trials involving over 17,000 patients determined that 50.2% and 17.5% of patients treated with GLP-1RAs (exenatide, semaglutide & liraglutide) experienced a weight loss of 5% and 10% compared to placebo, and that patients without type 2 diabetes achieved a significantly greater weight loss compared to those with diabetes (Vosoughi et al, 2022)
And at some point, people discover that we can make molecules that mimic that hormone and achieve the same action
Quick Answer: GLP-1 receptor agonists may reduce visceral fat alongside overall weight loss, though preferential visceral fat reduction is not a licensed indication in the UK
doi:10.1177/0391560318802160
doi: 10.1016/s0739-7240(99)00015-6
I have had colleagues refer patients to me to see if I think they are candidates for MHT, she says